Xeris Biopharma Holdings Inc (XERS)
3.09
+0.05
(+1.64%)
USD |
NASDAQ |
Nov 22, 16:00
3.085
0.00 (0.00%)
After-Hours: 20:00
Xeris Biopharma Holdings Revenue (Annual): 163.91M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 163.91M |
| December 31, 2022 | 110.25M |
| December 31, 2021 | 49.59M |
| December 31, 2020 | 20.44M |
| Date | Value |
|---|---|
| December 31, 2019 | 2.722M |
| December 31, 2018 | 2.423M |
| December 31, 2017 | 1.556M |
| December 31, 2016 | 1.075M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
2.722M
Minimum
2019
163.91M
Maximum
2023
69.38M
Average
49.59M
Median
2021
Revenue (Annual) Benchmarks
| Zevra Therapeutics Inc | 27.46M |
| NovaBay Pharmaceuticals Inc | 14.73M |
| Palatin Technologies Inc | 4.490M |
| iBio Inc | 0.225M |
| Theriva Biologics Inc | -- |